347 related articles for article (PubMed ID: 26569382)
1. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.
Wen QJ; Yang Q; Goldenson B; Malinge S; Lasho T; Schneider RK; Breyfogle LJ; Schultz R; Gilles L; Koppikar P; Abdel-Wahab O; Pardanani A; Stein B; Gurbuxani S; Mullally A; Levine RL; Tefferi A; Crispino JD
Nat Med; 2015 Dec; 21(12):1473-80. PubMed ID: 26569382
[TBL] [Abstract][Full Text] [Related]
2. Heat shock protein 90 inhibitors induce cell differentiation via the ubiquitin-dependent aurora kinase A degradation in a MPLW515L mouse model of primary myelofibrosis.
Wang F; Zhang H; He B; Liu Z; Wu X; Liu Y; Xu X; Gou X; Wang H; Yang Q
Hematol Oncol; 2023 Aug; 41(3):474-486. PubMed ID: 36422297
[TBL] [Abstract][Full Text] [Related]
3. c-Myc Is a Major Determinant for Antitumor Activity of Aurora A Kinase Inhibitor MLN8237 in Thyroid Cancer.
Li Y; Li X; Pu J; Yang Q; Guan H; Ji M; Shi B; Chen M; Hou P
Thyroid; 2018 Dec; 28(12):1642-1654. PubMed ID: 30226440
[No Abstract] [Full Text] [Related]
4. Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice.
Ozono Y; Shide K; Kameda T; Kamiunten A; Tahira Y; Sekine M; Akizuki K; Nakamura K; Iwakiri H; Sueta M; Hidaka T; Kubuki Y; Yamamoto S; Hasuike S; Sawaguchi A; Nagata K; Shimoda K
Leukemia; 2021 Feb; 35(2):454-467. PubMed ID: 32472085
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathways: induction of polyploidy as a novel differentiation therapy for leukemia.
Krause DS; Crispino JD
Clin Cancer Res; 2013 Nov; 19(22):6084-8. PubMed ID: 23963861
[TBL] [Abstract][Full Text] [Related]
6. Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL.
Wen Q; Goldenson B; Silver SJ; Schenone M; Dancik V; Huang Z; Wang LZ; Lewis TA; An WF; Li X; Bray MA; Thiollier C; Diebold L; Gilles L; Vokes MS; Moore CB; Bliss-Moreau M; Verplank L; Tolliday NJ; Mishra R; Vemula S; Shi J; Wei L; Kapur R; Lopez CK; Gerby B; Ballerini P; Pflumio F; Gilliland DG; Goldberg L; Birger Y; Izraeli S; Gamis AS; Smith FO; Woods WG; Taub J; Scherer CA; Bradner JE; Goh BC; Mercher T; Carpenter AE; Gould RJ; Clemons PA; Carr SA; Root DE; Schreiber SL; Stern AM; Crispino JD
Cell; 2012 Aug; 150(3):575-89. PubMed ID: 22863010
[TBL] [Abstract][Full Text] [Related]
7. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
Dauch D; Rudalska R; Cossa G; Nault JC; Kang TW; Wuestefeld T; Hohmeyer A; Imbeaud S; Yevsa T; Hoenicke L; Pantsar T; Bozko P; Malek NP; Longerich T; Laufer S; Poso A; Zucman-Rossi J; Eilers M; Zender L
Nat Med; 2016 Jul; 22(7):744-53. PubMed ID: 27213815
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF
Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923
[TBL] [Abstract][Full Text] [Related]
9. Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes.
Manshouri T; Verstovsek S; Harris DM; Veletic I; Zhang X; Post SM; Bueso-Ramos CE; Estrov Z
PLoS One; 2019; 14(9):e0222912. PubMed ID: 31569199
[TBL] [Abstract][Full Text] [Related]
10. Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial.
Gangat N; Marinaccio C; Swords R; Watts JM; Gurbuxani S; Rademaker A; Fought AJ; Frankfurt O; Altman JK; Wen QJ; Farnoud N; Famulare CA; Patel A; Tapia R; Vallapureddy RR; Barath S; Graf A; Handlogten A; Zblewski D; Patnaik MM; Al-Kali A; Dinh YT; Englund Prahl K; Patel S; Nobrega JC; Tejera D; Thomassen A; Gao J; Ji P; Rampal RK; Giles FJ; Tefferi A; Stein B; Crispino JD
Clin Cancer Res; 2019 Aug; 25(16):4898-4906. PubMed ID: 31061068
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Aurora A enhances radiosensitivity in selected lung cancer cell lines.
Liu N; Wang YA; Sun Y; Ecsedy J; Sun J; Li X; Wang P
Respir Res; 2019 Oct; 20(1):230. PubMed ID: 31647033
[TBL] [Abstract][Full Text] [Related]
12. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L.
Taksin AL; Couedic JP; Dusanter-Fourt I; Massé A; Giraudier S; Katz A; Wendling F; Vainchenker W; Casadevall N; Debili N
Blood; 1999 Jan; 93(1):125-39. PubMed ID: 9864154
[TBL] [Abstract][Full Text] [Related]
13. Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer.
Kozyreva VK; Kiseleva AA; Ice RJ; Jones BC; Loskutov YV; Matalkah F; Smolkin MB; Marinak K; Livengood RH; Salkeni MA; Wen S; Hazard HW; Layne GP; Walsh CM; Cantrell PS; Kilby GW; Mahavadi S; Shah N; Pugacheva EN
Mol Cancer Ther; 2016 Aug; 15(8):1809-22. PubMed ID: 27235164
[TBL] [Abstract][Full Text] [Related]
14. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
15. Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models.
Kogiso M; Qi L; Braun FK; Injac SG; Zhang L; Du Y; Zhang H; Lin FY; Zhao S; Lindsay H; Su JM; Baxter PA; Adesina AM; Liao D; Qian MG; Berg S; Muscal JA; Li XN
Clin Cancer Res; 2018 May; 24(9):2159-2170. PubMed ID: 29463553
[No Abstract] [Full Text] [Related]
16. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
Rumi E; Cazzola M
Blood; 2017 Feb; 129(6):680-692. PubMed ID: 28028026
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma.
Park SI; Lin CP; Ren N; Angus SP; Dittmer DP; Foote M; Parton T; Bhatt AP; Fedoriw YD; Roth DP; Cann ML; Johnson GL; Damania B
Target Oncol; 2019 Oct; 14(5):563-575. PubMed ID: 31429028
[TBL] [Abstract][Full Text] [Related]
18. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma.
Romain C; Paul P; Kim KW; Lee S; Qiao J; Chung DH
J Pediatr Surg; 2014 Jan; 49(1):159-65. PubMed ID: 24439602
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of ALK5 inhibition in myelofibrosis.
Yue L; Bartenstein M; Zhao W; Ho WT; Han Y; Murdun C; Mailloux AW; Zhang L; Wang X; Budhathoki A; Pradhan K; Rapaport F; Wang H; Shao Z; Ren X; Steidl U; Levine RL; Zhao ZJ; Verma A; Epling-Burnette PK
JCI Insight; 2017 Apr; 2(7):e90932. PubMed ID: 28405618
[TBL] [Abstract][Full Text] [Related]
20. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.
Ding YH; Zhou ZW; Ha CF; Zhang XY; Pan ST; He ZX; Edelman JL; Wang D; Yang YX; Zhang X; Duan W; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():425-64. PubMed ID: 25624750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
